

Joe M O'sullivan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10815045/publications.pdf>

Version: 2024-02-01

89
papers

9,305
citations

94269

37
h-index

51492

86
g-index

89
all docs

89
docs citations

89
times ranked

10081
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	0.8	40
2	Dose estimation after a mixed field exposure: Radium-223 and intensity modulated radiotherapy. <i>Nuclear Medicine and Biology</i> , 2022, 106-107, 10-20.	0.3	5
3	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	6.3	173
4	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	2.3	29
5	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
6	Hormone therapy use and the risk of acute kidney injury in patients with prostate cancer: a population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1055-1062.	2.0	4
7	Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4549-4556.	3.2	5
8	Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5Åyr in the CHHiP trial (CRUK/06/016). <i>European Urology Oncology</i> , 2021, 4, 980-992.	2.6	14
9	Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease. <i>Journal of Clinical Oncology</i> , 2021, 39, 3022-3033.	0.8	24
10	Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. <i>European Urology Oncology</i> , 2020, 3, 455-463.	2.6	17
11	The Risk of Cardiovascular Disease in Prostate Cancer Patients Receiving Androgen Deprivation Therapies. <i>Epidemiology</i> , 2020, 31, 432-440.	1.2	22
12	Use of bisphosphonates and other bone supportive agents in the management of prostate cancer – A UK perspective. <i>International Journal of Clinical Practice</i> , 2020, 74, e13611.	0.8	0
13	A novel tool for improving the interpretation of isotope bone scans in metastatic prostate cancer. <i>British Journal of Radiology</i> , 2020, 93, 20200775.	1.0	2
14	Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. <i>NAR Cancer</i> , 2020, 2, zcaa012.	1.6	8
15	Targeted Alpha Therapy: Current Clinical Applications. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 404-417.	0.7	48
16	Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression. <i>British Journal of Cancer</i> , 2020, 122, 1315-1323.	2.9	15
17	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
18	Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT). <i>Pilot and Feasibility Studies</i> , 2019, 5, 102.	0.5	8

#	ARTICLE	IF	CITATIONS
19	Where Do We See Alpha Emitters in Clinical Practice? A Radiation Oncology Perspective. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S31-S33.	0.2	1
20	Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. <i>BMC Cancer</i> , 2019, 19, 12.	1.1	36
21	Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 348-355.e5.	0.9	27
22	Mechanistic Modeling of Radium-223 Treatment of Bone Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1221-1230.	0.4	8
23	The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, e51-e52.	0.9	21
24	The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1179-1189.	0.4	33
25	Reply to "Single high dose versus repeated bone-targeted radionuclide therapy". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 515-517.	3.3	0
26	Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. <i>British Journal of Radiology</i> , 2018, 91, 20170795.	1.0	9
27	Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. <i>European Urology</i> , 2018, 73, 427-435.	0.9	84
28	Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e411-e419.	0.9	36
29	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	2.6	19
30	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	5.1	90
31	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet</i> , The, 2018, 392, 2353-2366.	6.3	901
32	A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1319-1327.	3.3	15
33	Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life. <i>Radiation Oncology</i> , 2017, 12, 53.	1.2	6
34	The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). <i>Urology</i> , 2017, 104, 150-159.	0.5	29
35	A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases. <i>Physics in Medicine and Biology</i> , 2017, 62, 2859-2870.	1.6	6
36	Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. <i>European Journal of Cancer</i> , 2017, 71, 1-6.	1.3	45

#	ARTICLE	IF	CITATIONS
37	Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 620-629.	3.3	18
38	Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 42-52.e8.	0.9	75
39	A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy. <i>Radiation Oncology</i> , 2017, 12, 124.	1.2	9
40	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1530-1541.	0.8	54
41	StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial. <i>Trials</i> , 2016, 17, 560.	0.7	14
42	Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. <i>European Urology</i> , 2016, 70, 875-883.	0.9	67
43	Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. <i>Lancet Oncology</i> , The, 2016, 17, 1306-1316.	5.1	259
44	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. <i>Lancet Oncology</i> , The, 2016, 17, 1047-1060.	5.1	941
45	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1163-1177.	6.3	1,570
46	Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5082-5082.	0.8	20
47	Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-resistant Prostate Cancer: Optimizing Clinical Practice in Nuclear Medicine Centers. <i>The Journal of Oncopathology</i> , 2015, 3, 1-25.	0.1	10
48	Cellular signalling effects in high precision radiotherapy. <i>Physics in Medicine and Biology</i> , 2015, 60, 4551-4564.	1.6	15
49	Conventional in vivo irradiation procedures are insufficient to accurately determine tumor responses to non-uniform radiation fields. <i>International Journal of Radiation Biology</i> , 2015, 91, 257-261.	1.0	5
50	A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer. <i>Journal of Cancer Survivorship</i> , 2015, 9, 431-440.	1.5	53
51	Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. <i>Lancet Oncology</i> , The, 2015, 16, 1605-1616.	5.1	126
52	Time and Cell Type Dependency of Survival Responses in Co-cultured Tumor and Fibroblast Cells after Exposure to Modulated Radiation Fields. <i>Radiation Research</i> , 2015, 183, 656-664.	0.7	10
53	Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself. <i>PLoS ONE</i> , 2015, 10, e0118187.	1.1	17
54	Inverse planned constant dose rate volumetric modulated arc therapy (VMAT) as an efficient alternative to five-field intensity modulated radiation therapy (IMRT) for prostate. <i>Journal of Radiotherapy in Practice</i> , 2014, 13, 68-78.	0.2	7

#	ARTICLE	IF	CITATIONS
55	Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 219-231.	1.1	30
56	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 738-746.	5.1	433
57	Advantages and limitations of navigation-based multicriteria optimization (MCO) for localized prostate cancer IMRT planning. <i>Medical Dosimetry</i> , 2014, 39, 205-211.	0.4	26
58	Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions. <i>Radiotherapy and Oncology</i> , 2014, 110, 342-347.	0.3	72
59	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. <i>Lancet Oncology</i> , The, 2014, 15, 1397-1406.	5.1	351
60	Implications of Intercellular Signaling for Radiation Therapy: A Theoretical Dose-Planning Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 1148-1154.	0.4	20
61	A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2013, 63, 189-197.	0.9	154
62	Investigating the influence of respiratory motion on the radiation induced bystander effect in modulated radiotherapy. <i>Physics in Medicine and Biology</i> , 2013, 58, 8311-8322.	1.6	4
63	What is the Role of the Bystander Response in Radionuclide Therapies?. <i>Frontiers in Oncology</i> , 2013, 3, 215.	1.3	51
64	Bone-Targeting Radiopharmaceuticals Including Radium-223. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 71-78.	1.0	60
65	A Kinetic-Based Model of Radiation-Induced Intercellular Signalling. <i>PLoS ONE</i> , 2013, 8, e54526.	1.1	55
66	Use of radionuclides in metastatic prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 310-315.	0.5	14
67	Cell type-dependent uptake, localization, and cytotoxicity of 1.9 nm gold nanoparticles. <i>International Journal of Nanomedicine</i> , 2012, 7, 2673.	3.3	150
68	Relative biological effectiveness (RBE) and out-of-field cell survival responses to passive scattering and pencil beam scanning proton beam deliveries. <i>Physics in Medicine and Biology</i> , 2012, 57, 6671-6680.	1.6	15
69	Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor-Targeted Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 3822-3833.	3.2	53
70	A Computational Model of Cellular Response to Modulated Radiation Fields. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 250-256.	0.4	35
71	Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 549-558.	5.1	100
72	Neoadjuvant Hormone Therapy for Radical Prostate Radiotherapy: Bicalutamide Monotherapy vs. Luteinizing Hormone-Releasing Hormone Agonist Monotherapy: A Single-Institution Matched-Pair Analysis. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 190-195.	0.9	4

#	ARTICLE	IF	CITATIONS
73	DNA Damage Responses following Exposure to Modulated Radiation Fields. PLoS ONE, 2012, 7, e43326.	1.1	44
74	Dose, dose-rate and field size effects on cell survival following exposure to non-uniform radiation fields. Physics in Medicine and Biology, 2012, 57, 3197-3206.	1.6	43
75	Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. Journal of Clinical Oncology, 2012, 30, 8-8.	0.8	55
76	Assessing software upgrades, plan properties and patient geometry using intensity modulated radiation therapy (IMRT) complexity metrics. Medical Physics, 2011, 38, 2027-2034.	1.6	38
77	Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy. Radiotherapy and Oncology, 2011, 100, 412-416.	0.3	174
78	A phase I study of combined docetaxel and repeated high activity ¹⁸⁶ Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1990-1998.	3.3	29
79	Cell-Specific Radiosensitization by Gold Nanoparticles at Megavoltage Radiation Energies. International Journal of Radiation Oncology Biology Physics, 2011, 79, 531-539.	0.4	388
80	Out-of-Field Cell Survival Following Exposure to Intensity-Modulated Radiation Fields. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1516-1522.	0.4	83
81	Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles. Scientific Reports, 2011, 1, 18.	1.6	335
82	The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis. Journal of Cancer Survivorship, 2010, 4, 128-139.	1.5	126
83	A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy. Trials, 2010, 11, 86.	0.7	16
84	A study of the biological effects of modulated 6 MV radiation fields. Physics in Medicine and Biology, 2010, 55, 1607-1618.	1.6	29
85	Radiation-induced bystander signalling in cancer therapy. Nature Reviews Cancer, 2009, 9, 351-360.	12.8	703
86	Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor- κ B Transcription and Evasion of Apoptosis. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 746-759.	1.3	100
87	Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis, 2008, 29, 1148-1156.	1.3	119
88	Tumor Dosimetry on SPECT ¹⁸⁶ Re-HEDP Scans: Variations in the Results from the Reconstruction Methods Used. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 121-124.	0.7	2
89	Failure to Achieve a PSA Level \leq 1 ng/mL After Neoadjuvant LHRHa Therapy Predicts for Lower Biochemical Control Rate and Overall Survival in Localized Prostate Cancer Treated With Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1467-1471.	0.4	15